 BOSTON, Jan. 06, 2021 GLOBE NEWSWIRE -- Albireo Pharma, Inc. Nasdaq: ALBO, a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireos common stock. The stock options are exercisable at a price of 36.98 per share, the closing price of Albireos common stock on January 4, 2021, the grant date, and were granted as inducements material to the employees acceptance of employment with Albireo in accordance with Nasdaq Listing Rule 5635c4. Each stock option has a 10-year term and vests over a four-year period, subject to the employees continued service with Albireo through the applicable vesting dates. The vesting schedule for each stock option is 25 percent on the one-year anniversary of the employees start date with Albireo and 75 percent in 12 equal quarterly installments thereafter. The stock options are subject to the terms and conditions of Albireos 2020 Inducement Equity Incentive Plan. 